Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models.
“We’re doing well, but we can do even better by personalizing therapies,” said Roy Herbst, MD, PhD, of the Yale Cancer Center.
The experimental antibody BAY1905254 targets the newly discovered checkpoint ILDR2.
TLR9 agonist restores response to immunotherapy in people with advanced melanoma.
Study shows eight-month survival advantage for those not previously treated with chemotherapy.
Immunotherapy plus targeted therapy and chemotherapy extended progression-free survival by up to four months.
BLU-667 shrinks thyroid and lung cancers with RET gene alterations.
First-line combination therapy lowered the risk of death by 51 percent.
The cells’ immediate response was to change the mechanisms they use to evade treatment and start dividing again—in just a few days.
Kids born with nonchromosomal defects, such as congenital heart disease, have more than twice the risk for some childhood cancers.
An antibody present in the blood of women previously infected with the STI is associated with almost double the risk of the disease.
First-line immunotherapy combo improved progression-free survival in people with highly mutated lung tumors.
NCI director Norman Sharpless shares his vision at American Association for Cancer Research annual meeting.
Immunotherapy lowered the likelihood of relapse after surgery.
Dream Team aims to replace “watch and wait” with effective treatments.
Coming up at AACR: Chemotherapy can compromise CAR-T therapy and HER2 mutations may confer resistance to hormone therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.